The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM D			OMB APPROVAL OMB Number: 3235-0076 Estimated average burden burge per personale 4 00		
Notice of Exempt Offering of Securities					
1. Issuer's Identity					
CIK (Filer ID Number)	Previous Names	None	Entity Type		
0001885827		s (Cayman) Ltd	X Corporation		
Name of Issuer		(()))	Limited Partnershi	n	
Virax Biolabs Group Ltd					
Jurisdiction of Incorporation/Organ	ization		Limited Liability Co		
CAYMAN ISLANDS			General Partnersh	ip	
Year of Incorporation/Organization			Business Trust		
Over Five Years Ago			Other (Specify)		
X Within Last Five Years (Specify	Year) 2021				
Yet to Be Formed					
2. Principal Place of Business an	d Contact Information				
Name of Issuer					
Virax Biolabs Group Ltd					
Street Address 1		Street Address 2			
20 North Audley Street	State/Province/Country	ZIP/PostalCode	Phone Number of Is		
City London	UNITED KINGDOM	W1K 6LX	44 020 7788 7414	Suel	
3. Related Persons					
Last Name	First Name		Middle Name		
Foster	James		Alexander Cunliffe		
Street Address 1	Street Address 2				
20 North Audley Street					
City	State/Province/Co UNITED KINGDO	•	ZIP/PostalCode		
London Relationship: X Executive Officer		IVI	W1K 6LX		
Clarification of Response (if Neces					
	sary).				
Last Name	First Name		Middle Name		
Shaw	Cameron				
Street Address 1 20 North Audley Street	Street Address 2				
City	State/Province/Co	untry	ZIP/PostalCode		
London	UNITED KINGDO		W1K 6LX		
Relationship: X Executive Officer	X Director Promoter				
Clarification of Response (if Neces	sary):				
Last Name	First Name		Middle Name		
Norton	Evan				
Street Address 1	Street Address 2				
20 North Audley Street					
City	State/Province/Co		ZIP/PostalCode		
London	UNITED KINGDO	Μ	W1K 6LX		
Relationship: Executive Officer	X Director Promoter				

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name	
Erez	Yair		
Street Address 1	Street Address 2		
20 North Audley Street			
City	State/Province/Country	ZIP/PostalCode	
London	UNITED KINGDOM	W1K 6LX	
Clarification of Response (if Necessa			
	,		
Last Name	First Name	Middle Name	
Haight	Nelson	Maurice	
Street Address 1	Street Address 2		
20 North Audley Street			
City	State/Province/Country	ZIP/PostalCode	
London	UNITED KINGDOM	W1K 6LX	
Relationship: Executive Officer X	Director Promoter		
Clarification of Response (if Necessa	ary):		
Last Name	First Name	Middle Name	
		Middle Name	
Davis	Jason		
Street Address 1	Street Address 2		
20 North Audley Street			
City	State/Province/Country	ZIP/PostalCode	
London	UNITED KINGDOM	W1K 6LX	
Relationship: X Executive Officer	Director		
Clarification of Response (if Necessa	ary):		
Last Name	First Name	Middle Name	
George	Tomasz		
Street Address 1	Street Address 2		
20 North Audley Street			
City	State/Province/Country	ZIP/PostalCode	
London	UNITED KINGDOM	W1K 6LX	
		WIK OLA	
Clarification of Response (if Necessa			
Last Name	First Name	Middle Name	
Ternouth	Mark		
Street Address 1	Street Address 2		
20 North Audley Street			
City	State/Province/Country	ZIP/PostalCode	
London	UNITED KINGDOM	W1K 6LX	
Relationship: X Executive Officer			
Clarification of Response (if Necessa			

4. Industry Group

Agriculture	Health Care	Retailing
Banking & Financial Services	X Biotechnology	
Commercial Banking	Health Insurance	Technology
	Hospitals & Physicians	
Investing	Pharmaceuticals	
Pooled Investment Fund	Other Health Care	Other Technology
Is the issuer registered as	Manufacturing	Travel
an investment company under the Investment Company	Real Estate	Airlines & Airports
Act of 1940?	Commercial	Lodging & Conventions
Yes No	Construction	Tourism & Travel Services Other Travel Other
Business Services Energy	Cther Real Estate	
Coal Mining		
Electric Utilities		
Energy Conservation		
Environmental Services		
Oil & Gas		
Other Energy		

5. Issuer Size	
Revenue Range OR	Aggregate Net Asset Value Range
No Revenues	No Aggregate Net Asset Value
X \$1 - \$1,000,000	\$1 - \$5,000,000
\$1,000,001 - \$5,000,000	\$5,000,001 - \$25,000,000
\$5,000,001 - \$25,000,000	\$25,000,001 - \$50,000,000
\$25,000,001 - \$100,000,000	\$50,000,001 - \$100,000,000
Over \$100,000,000	Over \$100,000,000
Decline to Disclose	Decline to Disclose
Not Applicable	Not Applicable
	_

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

	Investment Compa	ny Act Section 3(c)	
Rule 504(b)(1) (not (i), (ii) or (iii))	Section 3(c)(1)	Section 3(c)(9)	
Rule 504 (b)(1)(i)	Section 3(c)(2)	Section 3(c)(10)	
Rule 504 (b)(1)(ii)			
Rule 504 (b)(1)(iii)	Section 3(c)(3)	Section 3(c)(11)	
X Rule 506(b)	Section 3(c)(4)	Section 3(c)(12)	
Rule 506(c)	Section 3(c)(5)	$\prod_{i=1}^{n} \text{Section } 3(c)(13)$	
Securities Act Section 4(a)(5)			
_	Section 3(c)(6)	Section 3(c)(14)	
	Section 3(c)(7)		
7. Type of Filing			
X New Notice Date of First Sale 2023-03-10 First Sale	Yet to Occur		
8. Duration of Offering			
Does the Issuer intend this offering to last more than one ye	ear? YesXNo		
9. Type(s) of Securities Offered (select all that apply)			
X Equity	Γ	Pooled Investment Fund Interests	
Debt		Tenant-in-Common Securities	
X Option, Warrant or Other Right to Acquire Another Secur	itv	Mineral Property Securities	
Security to be Acquired Upon Exercise of Option, Warrar			
Acquire Security		Other (describe)	
10. Business Combination Transaction			
Is this offering being made in connection with a business co or exchange offer?	mbination transaction,	such as a merger, acquisition Yes X No	
Clarification of Response (if Necessary):			
11. Minimum Investment			
Minimum investment accepted from any outside investor \$6) USD		
12. Sales Compensation			
Recipient	Recipient	CRD Number None	
H.C. Wainwright & Co.	375		
(Associated) Broker or Dealer 🔀 None	(Associat	ed) Broker or Dealer CRD Number $\overline{\mathrm{X}}$ None	
None	None		
Street Address 1	Street Add		
430 PARK AVENUE	4TH FLOO		
City		/ince/Country	ZIP/Postal Code
NEW YORK State(s) of Solicitation (select all that apply) Check "All States" or check individual States	NEW YOR	10022	
13. Offering and Sales Amounts			
Total Offering Amount \$4,000,000 USD or Indefinite	f.		
Total Amount Sold \$4,000,000 USD			

Total Remaining to be Sold \$0 USD or Indefinite

Clarification of Response (if Necessary):

The offering includes the sale of warrants which are exercisable immediately after issuance. The above offering amount does not include the proceeds to be received by the Company upon exercise of the warrant.

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$20	8,000 USD	Estimate
Finders' Fees	\$0 USD	Estimate

Clarification of Response (if Necessary):

The placement agent is also entitled to a management fee 40,000, non-accountable expenses \$35,000, accountable expenses \$50,000, and warrants to purchase up to 269,032 ordinary shares.

16. Use of Proceeds	

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD Estimate

Clarification of Response (if Necessary):

Issuer expects to use proceeds from the offering for working capital which includes payment of salaries to executive officers.

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Virax Biolabs Group Ltd	/s/ Jason Davis	Jason Davis	Chief Financial Officer	2023-03-14

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.